gastric cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients aged >=18 years;2.Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at study entry;3.Patients with histologically proven gastric and gastroesophageal junction (Siewert type III) carcinomas with newly diagnosed by gastroscopy;4.Surgically resectable, advanced gastric cancer (cT4a, N0-3, M0) on initial staging evaluation by contrast-enhanced CT of the chest, abdomen, and pelvis (according to the eighth edition of AJCC TNM staging system);5.Patients with adequate organ function, defined as no severe disfunction of the lungs, kidneys, heart, bone marrow, and clinical laboratory test value
Exclusion criteria
Exclusion criteria: 1.Siewert type I-II esophagogastric junction tumor and Patients with advanced gastric cancer of M1 in TNM staging on CT staging evaluation; 2.Patients with allergic constitution or with drug allergy; 3.Patients with active double primary malignancies; 4.Patients who are possibly pregnant, pregnant, unwilling to practice contraception during the study or breastfeeding; 5.Patients diagnosed with mental illness that they could have difficulty in participating in the trial; 6.Patients with history of previous abdominal inflammatory diseases (such as peritonitis, pancreatitis, cholecystitis, inflammatory bowel disease); 7.Patients with history of abdominal trauma; 8.Patients with history of cerebrovascular accident within past six months; 9.Patients with history of continuous systematic administration of corticosteroids within one month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of changes in treatment strategy; | — |
Secondary
| Measure | Time frame |
|---|---|
| sensitivity;specificity;accuracy;positive predictive value;negative predictive value;SUVmax:maximum standardized uptake value;PCI; | — |
Countries
China
Contacts
West China Hospital of Sichuan University